tbuckley/cabot-search huggingface dataset:
REG3A Polymorphism Is Associated with the Incidence of Extensive Chronic Gvhd after Allogeneic BMT
Authors: Daisuke Koyama, Makoto Murata, Ryo Hanajiri, Shingo Okuno, Sonoko Kamoshita, Jakrawadee Julamanee, Erina Takagi, Kotaro Miyao, Reona Sakemura, Tatsunori Goto, Aika Seto, Yukiyasu Ozawa, Koichi Miyamura, Seitaro Terakura, Tetsuya Nishida, Hitoshi Kiyoi
Journal: Blood (2016)
A Human Lymphoid Progenitor Capable of Circulating and Seeding the Thymus.
Authors: Emmanuelle M. Six, Delphine Bonhomme, Marta Monteiro, Kheira Beldjord, Alexandrine Garrigue, Liliane Dal Cortivo, Benedita Rocha, Alain Fischer, Marina Cavazzana-Calvo, Isabelle André-Schmutz
Journal: Blood (2007)
A Short Weekly Chemotherapy Regimen (ACOP-B) Followed by Involved Field Radiotherapy in Limited Stage Aggressive Non-Hodgkin Lymphoma. Multicentric Analyses of Toxicity, Efficacy and Long Term Follow up.
Authors: Maria Giuseppina Cabras, Roberto Freilone, Angela Mamusa, Paolo Dessalvi, Anna Tonso, Lorella Orsucci, Umberto Vitolo, Emanuele Angelucci
Journal: Blood (2006)
Comparison of Clinical Outcomes of Relapsed APL Patients Induced with ATO and Consolidated with Either an Autologous SCT or ATO Based Treatment Regimen.
Authors: Vikram Mathews, Biju George, Ezhilarasi Chendamarai, Kavitha M. Lakshmi, Auro Viswabandya, Alok Srivastava, Mammen Chandy
Journal: Blood (2007)
RIZ1 Is Downregulated during CML Progression and Displays Tumor Suppressor Properties in CML Cell Lines.
Authors: Naoto Takahashi, Elodie Pastural, Robert Lowsky, Emina Torlakovic, Magdalena Czader, Guillermo Garcia-Manero, Hesham M. Amin, C. Ronald Geyer, John DeCoteau
Journal: Blood (2006)
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients
Authors: Salo N. Ooft, Fleur Weeber, Krijn K. Dijkstra, Chelsea M. McLean, Sovann Kaing, Erik van Werkhoven, Luuk Schipper, Louisa Hoes, Daniel J. Vis, Joris van de Haar, Warner Prevoo, Petur Snaebjornsson, Daphne van der Velden, Michelle Klein, Myriam Chalabi, Henk Boot, Monique van Leerdam, Haiko J. Bloemendal, Laurens V. Beerepoot, Lodewyk Wessels, Edwin Cuppen, Hans Clevers, Emile E. Voest
Journal: Science Translational Medicine (2019)

There is a clear and unmet clinical need for biomarkers to predict responsiveness to chemotherapy for cancer. We developed an in vitro test based on patient-derived tumor organoids (PDOs) from metastatic lesions to identify nonresponders to standard-of-care chemotherapy in colorectal cancer (CRC). In a prospective clinical study, we show the feasibility of generating and testing PDOs for evaluation of sensitivity to chemotherapy. Our PDO test predicted response of the biopsied lesion in more than 80% of patients treated with irinotecan-based therapies without misclassifying patients who would have benefited from treatment. This correlation was specific to irinotecan-based chemotherapy, however, and the PDOs failed to predict outcome for treatment with 5-fluorouracil plus oxaliplatin. Our data suggest that PDOs could be used to prevent cancer patients from undergoing ineffective irinotecan-based chemotherapy.
HCT Outcome in Patients with Fanconi Anemia Transplanted at Adult Age
Authors: Marc Bierings, Carmem Bonfim, Regis Peffault De La Tour, Mahmoud Aljurf, Parinda A Mehta, Cora Knol, Farid Boulad, Abdelghani Tbakhi, Albert Esquirol, Grant McQuaker, Gulsan Ayhan Sucak, Tarek Ben Othman, Constantijn J.M. Halkes, Kirsty J Thomson, Dietger Niederwieser, Marco Zecca, Nicolaus Kröger, Mauricette Michallet, Antonio M Risitano, Gerhard Ehninger, Raphael Porcher, Carlo DuFour
Journal: Blood (2016)
RANKL Expressed by Acute Myeloid Leukemia Cells Impairs NK Cell-Mediated Immune Surveillance
Authors: Benjamin J Schmiedel, Constantin M Wende, Tina Baessler, Carolin Scheible, Stefan Wirths, Miyuki Azuma, Pascal Schneider, Ludger Grosse-Hovest, Lothar Kanz, Helmut R Salih
Journal: Blood (2010)
Marked Elevation of Serum Lactate Dehydrogenase (LDH) in Primary Myelofibrosis: Clinical and Prognostic Correlates
Authors: Sahrish Shah, Mythri Mudireddy, Daniela Barraco, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2016)
Erythroid-Lineage Specific Engraftment in Patients with Severe Hemoglobinopathy Following Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Paul M. Armistead, Mehrdad Mohseni, Roslyn Gerwin, Masood Iravani, Bahram Chardouli, Sharbano Rhostami, Ardeshir Ghavamzadeh, Jerome Ritz, Joseph H. Antin, Catherine Wu
Journal: Blood (2007)
Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party
Authors: Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Mariella D'Adda, Fabio Stagno, Luciano Levato, Angelo Michele Carella, Bruno Martino, Mario Tiribelli, Giovanna Rege Cambrin, Antonella Gozzini, Marzia Salvucci, Michele Cedrone, Elena Trabacchi, Emilio Usala, Anna Rita Scortechini, Luigia Luciano, Simona Soverini, Giuliana Alimena, Michele Cavo, Giovanni Martinelli, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Gianantonio Rosti
Journal: Blood (2016)
Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia
Authors: Jordi Ribera, Mar Mallo, Lurdes Zamora, Neus Solanes, Susana Vives, Montserrat Batlle, Ramon Guàrdia, Santiago Mercadal, Lourdes Escoda, Josep F. Nomdedeu, Marta Pratcorona, Jordi Esteve, Joaquín Martínez-López, Mar Tormo, Joaquín Sánchez, Rocío Ruiz, Erica Morán, Marta Cabezón, Sílvia Marcé, Diana Domínguez, Isabel Granada, Jordi Juncà, Eulàlia Genescà, Fuensanta Millá, Evarist Feliu, Francesc Sole, Josep-Maria Ribera
Journal: Blood (2016)
Antithymocyte Globulin-Based Prophylaxis for Graft Versus Host Disease Compared to Post-Transplant Cyclophosphamide-Based Prophylaxis in Matched Unrelated Donor Transplantation
Authors: Sara Redondo Velao, Mi Kwon, Diana Champ, MJ Pascual Cascon, Pascual Balsalobre, J Diez, I Vidales Mancha, David Serrano, Noemi Fernandez, Javier Anguita, Ismael Buño, Jorge Gayoso, Jose Luis Diez-Martin
Journal: Blood (2016)
CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells.
Authors: Sonia Vallet, Noopur Raje, Kenji Ishitsuka, Teru Hideshima, Klaus Podar, Tanyel Kizeltepe, Hiroshi Yasui, Shweta Chhetri, Enrique M. Ocio, Janice Jin, Yutaka Okawa, Hiroshi Ikeda, Mario Boccadoro, Kenneth C. Anderson
Journal: Blood (2006)
Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment
Authors: Elsa Maitre, Edouard Cornet, Xavier Troussard
Journal: American Journal of Hematology (2019)

Abstract Disease overview Hairy cell leukemia (HCL) and HCL‐like disorders, including HCL variant (HCL‐V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature lymphoid B‐cell disorders. They are characterized by the identification of hairy cells, a specific genetic profile, a different clinical course and the need for appropriate treatment. Diagnosis Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL immunologic score of three or four based on the CD11C, CD103, CD123, and CD25 expression. Also, the trephine biopsy which makes it possible to specify the degree of tumoral medullary infiltration and the presence of BRAF V600E somatic mutation. Risk stratification Progression of patients with HCL is based on a large splenomegaly, leukocytosis, a high number of hairy cells in the peripheral blood and the immunoglobulin heavy chain variable region gene mutational status. The VH4‐34 positive HCL cases are associated with poor prognosis. Treatment Risk adapted therapy with purine nucleoside analogs (PNA) are indicated in symptomatic first line HCL patients. The use of PNA followed by rituximab represents an alternative option. Management of progressive or refractory disease is based on the use of BRAF inhibitors associated or not with MEK inhibitors, recombinant immunoconjugates targeting CD22 or BCR inhibitors.
Comparable Disease-Free and Overall Survival After “Well-Matched” Unrelated Donor and Matched Sibling Donor Transplantation in Acute Myeloid Leukemia with Adverse Risk Karyotype in First Complete Remission: A Report From the Acute Leukemia Working Committee of the Centre for International Blood and Marrow Transplant Research.
Authors: Vikas Gupta, Martin S. Tallman, Wensheng He, Brent Logan, John F. DiPersio, Donald W. Bunjes, Daniel J. Weisdorf
Journal: Blood (2009)
Variability in Antifungal Use for Pediatric Acute Myeloid Leukemia At Children's Hospitals Across the United States
Authors: Marko Kavcic, Brian T. Fisher, Jeffrey S. Gerber, Kateri H. Leckerman, Yimei Li, Yuan-Shung Huang, Alix E. Seif, Kari Torp, Rochelle Bagatell, Richard Aplenc
Journal: Blood (2012)
Irradiated Third Party Peripheral Blood Mononuclear Cells Enhance Umbilical Cord Blood Engraftment.
Authors: Tulin Budak-Alpdogan, Gajan Jeganathan, Kuo-Chieh Lee, Zbigniew Roger Mrowiec, Daniel Medina, Dennis Todd, Dirk Moore, Joseph Bertino, Roger Strair
Journal: Blood (2009)
In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma
Authors: Richard W Groen, Michael van der Veer, Frans M Hofhuis, Berris van Kessel, Michel de Weers, Paul W.H.I. Parren, Henk M Lokhorst, Tuna Mutis, Anton Martens
Journal: Blood (2010)
Mcl-1 Dependence Predicts Response To Vorinostat and Gemtuzumab Ozogamicin In Acute Myeloid Leukemia
Authors: William E. Pierceall, Ryan Lena, Bruno C. Medeiros, Elihu H. Estey, Noel Blake, Michael Elaschoff, Michael Cardone, Roland B. Walter
Journal: Blood (2013)
Early detection and risk stratification of gastric cancer are likely to be refined with biopsies targeted through high-resolution-enhanced imaging
Authors: Marnix Jansen, Matthew Banks
Journal: Gut (2019)

We thank Dr Ghisa1 and colleagues for their kind interest in our recently published BSG guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.2 

The introduction of advanced endoscopic imaging technologies has led to a re-appreciation of the fact that the progression of mucosal atrophy in the chronically inflamed stomach over time occurs in a patch-wise fashion.3 4 In particular, gastric intestinal metaplasia arises as well delineated islands within the gastric mucosa.5 These islands can be visualised using high-definition endoscopy and there is now good evidence that endoscopy-lead risk stratification correlates well with histology and operative link on gastric intestinal metaplasia (OLGIM) stages.6–8 These studies have provided important impetus for us to advance endoscopy-lead risk stratification in our …
Distinct Roles Of Antithrombin-Dependent Antithrombotic Agents (Lovenox, Fondaparinux) and Direct Anti-Xa Anti-Coagulant (Apixaban) On The Inhibition Of Thrombin Generation Induced By Human Pancreatic (BXPC3) and Human Breast (MCF7) Cells
Authors: Aurélie Rousseau, Patrick Van Dreden, Elisabeth Mbemba, Mohamed Hatmi, Amir Kharterchi, Marie-Paule Roman, Ismail Elalamy, Grigoris T Gerotziafas
Journal: Blood (2013)
Decision Analysis of Allogeneic Hematopoietic Stem Cell Transplantation Versus Chemotherapy in Cytogenetically Standard-Risk Acute Myeloid Leukemia in First Complete Remission: The Impact of FLT3-ITD Profile
Authors: Saiko Kurosawa, Hiroki Yamaguchi, Takuhiro Yamaguchi, Keiko Fukunaga, Shunsuke Yui, Heiwa Kanamori, Kensuke Usuki, Nobuhiko Uoshima, Masamitsu Yanada, Katsuhiro Shono, Toshimitsu Ueki, Ishikazu Mizuno, Shingo Yano, Jin Takeuchi, Junya Kanda, Hiroshi Okamura, Kinuko Tajima, Yoshihiro Inamoto, Koiti Inokuchi, Takahiro Fukuda
Journal: Blood (2014)
Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression.
Authors: Xavier Poiré, Ernesto Diaz-Flores, Rachel Joy Bergerson, Dorie Sher, Olatoyosi Odenike, Kevin Shannon, David Largaespada, Wendy Stock
Journal: Blood (2009)
Clinical Impact of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsy In the Diagnosis of Patients with Lymphoma Who Have No Superficial Lymphadenopathies
Authors: Naoe Goto, Ichiro Yasuda, Hisashi Tsurumi, Shinpei Doi, Takeshi Hara, Takuji Iwashita, Senji Kasahara, Masanori Nakashima, Nobuhiro Kanemura, Seiji Adachi, Takahiro Yamauchi, Tsuyoshi Takami, Hisataka Moriwaki
Journal: Blood (2010)
T-Cell Depletion in Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective EBMT Analysis.
Authors: Johannes Schetelig, Donald Milligan, Dietger Niederwieser, Liisa Volin, J. Maertens, Alois Gratwohl, Martin Bornhaeuser, Michel Van Gelder, Ronald Brand, T. M. de Witte, Peter Dreger
Journal: Blood (2009)
Patritumab augments anti-tumor immune response of adoptive transfer of autologous T cells for breast cancer PDX models
Authors: Takeshi Kotake, Eiji Suzuki, Fengling Pu, Tatsuki Kataoka, Masahiro Hirata, Tomomi Nishimura, Kei Iida, Li Liu, Masakazu Toi
Journal: Annals of Oncology (2019)
Rationale and Design of a Phase IIb/III Open-Label, Multicenter Study of Dabigatran Etexilate for Venous Thromboembolism in Children: The Diversity Study
Authors: Manuela Albisetti, Ivan Manastirski, Martina Brueckmann, Savion Gropper, Bushi Wang, Igor Tartakovsky, Branislav Biss, Fenglei Huang, Lesley G Mitchell, Leonardo R. Brandão, Jacqueline ML Halton
Journal: Blood (2016)
Nuclear Area Predicts Outcome In Peripheral T-Cell Lymphoma, Not Otherwise Specified: Morphometric Image and Immunohistochemical Analyses of 78 Patients
Authors: Daisuke Niino, Yoshizo Kimura, Junichi Kiyasu, Masanori Takeuchi, Tadashi Yoshino, Shigeo Nakamura, Koichi Ohshima
Journal: Blood (2010)
Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid
Authors: Natalie McCormick, Zachary S. Wallace, Chana A. Sacks, John Hsu, Hyon K. Choi
Journal: Arthritis & Rheumatology (2019)

Objective Billions of public dollars are spent each year on biologic disease‐modifying antirheumatic drugs ( DMARD s), but the drivers of recent increases in biologic DMARD spending are unclear. This study was undertaken to characterize changes in total spending and unit prices for biologic DMARD s in Medicare and Medicaid programs and quantified the major sources of these spending increases. Methods We accessed drug spending data from years 2012–2016, covering all Medicare Part B (fee‐for‐service), Medicare Part D, and Medicaid enrollees. After calculating 5‐year changes in total spending and unit prices for each biologic DMARD as well as in aggregate, we performed standard decomposition analyses to isolate 4 sources of spending growth: drug prices, uptake (number of recipients), treatment intensity (mean number of doses per claim), and treatment duration (annual number of claims per recipient), both excluding and including time‐varying rebates. Results From 2012 to 2016, annual spending on public‐payer claims for the 10 biologic DMARD s included in this study more than doubled ($3.8 billion to $8.6 billion), with median drug price increases of 51% in Medicare Part D (mean 54%) and 8% in Medicare Part B (mean 21%). With adjustment for general inflation, unit price increases alone accounted for 57% of the 5‐year, $3.0 billion spending increase in Part D, while 37% of the spending increase was from increased uptake. Accounting for time‐varying rebates, prices were still responsible for 54% of increased spending. Unit prices and spending were lower under Medicaid than under Medicare Part D, though temporal trends and contributors were similar. Conclusion Postmarket drug price changes alone account for the majority of the recent spending growth in biologic DMARD s. Policy interventions targeting price increases, particularly those under Medicare Part D plans, may help mitigate financial burdens for public payers and biologic DMARD recipients.
Intracoronary shear-related upregulation of platelet p-selectin, platelet-monocyte aggregation and monocyte CD11B despite the use of aspirin and clopidogrel
Authors: Andy S. Yong, Gabrielle J. Pennings, Michael Chang, Afiqah Hamzah, Tommy Chung, David Brieger, Masud Behnia, Martin K. Ng, Harry C. Lowe, Leonard Kritharides
Journal: Circulation (2010)
Post-Transcriptional Modifications Explain the Overexpression of CCND2 in Multiple Myeloma
Authors: Irena Misiewicz-Krzeminska, Maria Eugenia Sarasquete, Carolina Vicente-Dueñas, Patryk Krzeminski, Katarzyna Wiktorska, Dalia Quwaider, Elizabeta A. Rojas, Rocío Corral, Luis Antonio Corchete, Ana A. Martin, Fernando Escalante, Abelardo Bárez, Juan Luis Garcia, Isidro Sanchez-Garcia, Ramón García-Sanz, Jesus F. San Miguel, Norma Carmen Gutierrez
Journal: Blood (2014)
Avascular Necrosis(AVN) and Surgical Intervention In Pediatric Acute Lymphoblastic Leukemia(ALL): A Retrospective Cohort Analysis From The Pediatric Health Information Systems (PHIS)
Authors: Mallorie B Heneghan, Susan R. Rheingold, Yimei Li, Alix E. Seif, Yuan-Shung Huang, Brian T. Fisher, Richard Aplenc
Journal: Blood (2013)
Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study
Authors: Frederic Baron, Fabio Efficace, Laura Cannella, Franco Mandelli, Roelof Willemze, Petra Muus, Jean-Pierre Marie, Dario Ferrero, Marlies Dictus, Paola Fazi, Edoardo La Sala, Jean-Henri Bourhis, Francesco Fabbiano, Alberto Bosi, Marco Sborgia, Giovanni Martinelli, Dominique Bron, Maria C. Petti, Constantijn J.M. Halkes, Walter J.F.M. van der Velden, Mario Boccadoro, Sergio Amadori, Robert A. Zittoun, Stefan Suciu
Journal: Blood (2016)
Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML
Authors: Alexander V Lavrov, Oksana A Ustaeva, Elmira P Adilgereeva, Svetlana A Smirnikhina, Ekaterina Chelysheva, Oleg Shukhov, Yuriy V Shatokhin, Sergey V Mordanov, Anna G Turkina, Sergey Kutsev
Journal: Blood (2016)
KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial
Authors: Jason Gotlib, Daniel J. DeAngelo, Tracy I. George, Christopher L. Corless, Andrea Linder, Cheryl Langford, Catherine Dutreix, Stefan Gross, Zariana Nikolova, Timothy Graubert
Journal: Blood (2010)
The Novel Proteasome Inhibitor MLN2238 (Ixazomib) Induces Death In CLL Cells In Vitro and Potentiates Lethality Of Fludarabine and The BCL2 Inhibitor At-101
Authors: Kasyapa S. Chitta, Aneel Paulus, Sharoon Akhtar, Maja Kuranz, Kena Miller, Candido E. Rivera, Vivek Roy, James M. Foran, Aisha Masood, Asher Chanan-Khan
Journal: Blood (2013)
Adolescent and young adult oncology—past, present, and future
Authors: Allison G. Close, Alexandra Dreyzin, Kimberly D. Miller, Brittani K.N. Seynnaeve, Louis B. Rapkin
Journal: CA A Cancer Journal for Clinicians (2019)

There are nearly 70,000 new cancer diagnoses made annually in adolescents and young adults (AYAs) in the United States. Historically, AYA patients with cancer, aged 15 to 39 years, have not shown the same improved survival as older or younger cohorts. This article reviews the contemporary cancer incidence and survival data through 2015 for the AYA patient population based on the National Cancer Institute's Surveillance, Epidemiology, and End Results registry program and the North American Association of Central Cancer Registries. Mortality data through 2016 from the Centers for Disease Control and Prevention's National Center for Health Statistics are also described. Encouragingly, absolute and relative increases in 5-year survival for AYA cancers have paralleled those of childhood cancers since the year 2000. There has been increasing attention to these vulnerable patients and improved partnerships and collaboration between adult and pediatric oncology; however, obstacles to the care of this population still occur at multiple levels. These vulnerabilities fall into 3 significant categories: research efforts and trial enrollment directed toward AYA malignancies, access to care and insurance coverage, and AYA-specific psychosocial support. It is critical for providers and health care delivery systems to recognize that the AYA population remains vulnerable to provider and societal complacency.
The Embt Risk Score Predicts the Outcome of Patients with Leukaemia Receiving Single Umbilical Cord Blood Transplantation
Authors: Xiaoyu Zhu, Baolin Tang, Changcheng Zheng, Huilan Liu, Liangquan Geng, Juan Tong, Lei Zhang, Xuhan Zhang, Wen Yao, Kaidi Song, Xingbing Wang, Kaiyang Ding, Zimin Sun
Journal: Blood (2016)
Best supportive care for advanced lung cancer patients aged 85 and older
Authors: Taisuke Kazuyori, Yoshitaka Seki, Akihito Satou, Syouta Fujimoto, Masami Yamada, Yumie Yamanaka, Ikumi Fujisaki, Kyuuto Odashima, Aya Seki, Takeo Ishikawa, Kazuyoshi Kuwano
Journal: Annals of Oncology (2019)
The Evolution of Spiritual Care in the NCCN Distress Management Guidelines
Authors: George Handzo, Jill M. Bowden, Stephen King
Journal: Journal of the National Comprehensive Cancer Network (2019)

Spiritual care and chaplaincy have been part of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Distress Management since the first meeting of the panel in 1997, possibly the first time this degree of spiritual care and chaplaincy care integration occurred in cancer care. Since that time, the chaplaincy care section of the guidelines, especially chaplain assessment categories derived from a spiritual care assessment, have provided a major resource for healthcare chaplaincy and have served as a model for integrating chaplaincy into the overall team practice of healthcare. However, this section of the NCCN Guidelines has not been substantially updated since it was originally written. During those 20 years, the practice of healthcare chaplaincy and the research that supports it have grown substantially. In the last year, at the request of the panel, we have updated the chaplaincy care section to fully integrate recently published evidence in spiritual care in healthcare, adding more value to this important set of guidelines. Those updates appear in the 2019 version of the NCCN Guidelines. This article discusses the history of chaplaincy involvement in the NCCN Guidelines for Distress Management and the precedent it set for the integration of chaplaincy in other efforts that followed. Integration of this section of the Guidelines into the spiritual care practice at Memorial Sloan Kettering Cancer Center is presented as an example of how these guidelines can be put into practice to improve patient care. Finally, a summary of the recent research by Drs. Kenneth Pargament and Julie Exline is presented as the foundation for the revised chaplain assessment categories and interventions.
Lymph Node Derived CLL Cells Have a More Activated Phenotype and Better Antigen Presentation Capabilities Compared To Those From The Peripheral Blood
Authors: Andrea GS Buggins, Marta Pasikowska, Elisabeth J Walsby, Kirsty M Cuthill, Maria Longhi, Emma Hamilton, Linda Barber, Chris Fegan, Chris Pepper, Stephen Devereux
Journal: Blood (2013)